UT MD Anderson
Houston, Texas, 77030, United States
Location contact
Lisa Lowenstein, PHD
CONTACT
Lisa Lowenstein, PHD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07720141
The goal of this research study is to compare two different ways to increase lung cancer screening rates for tobacco quitline clients.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Houston, Texas, 77030, United States
Lisa Lowenstein, PHD
CONTACT
Lisa Lowenstein, PHD
PRINCIPAL_INVESTIGATOR
Primary Objective/Aim:
Aim 1. Compare two dissemination strategies that vary in intensity on demand for LCS. We hypothesize that there will be a higher demand for LCS in the high-touch strategy arm compared to the low-touch strategy arm, as demonstrated by self-reported LCS completion, as well as scheduling a visit with a health care provider to discuss LCS.
Secondary Objectives/Aim:
Aim 2. Evaluate the impact on reach of the high-touch and low-touch strategies to disseminate LCS educational materials (i.e., view of the decision aid or participation in a decision coaching visit). We expect that disseminating the LCS educational materials through the high-touch strategy will result in higher reach than delivering the LCS educational materials through the low-touch strategy.
Aim 3. Evaluate the financial sustainability and cost-effectiveness of the two approaches of disseminating LCS educational materials. We expect that the high-touch strategy will require a greater financial commitment and stronger partnerships between quitline service providers, state department of health, and health care systems, it will be a cost-effective dissemination strategy compared to the low-touch strategy (emailing/texting).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Quitline Client
Quitline client participants must meet the criteria for LCS with regards to age (50 to 80 years) and smoking history (20+ pack-years). This project will not re-confirm quitline client participant eligibility for screening. Tobacco treatment specialists will elicit study interest from only eligible quitline clients.
Representative of the Quitline Community
Representative of the Quitline Community will include any employee of the quitline service provider, representative from an organization that collaborates or funds a tobacco quitline, and/or a representative of the state department of health. All individuals will be adults (18 years and older) and able to speak English.
Representative of the Healthcare Sector
Representative of the healthcare sector will include any adult who works in healthcare, including but not limited to physicians, healthcare administrative leaders/managers, nurses, advanced practice providers. All individuals will be adults (18 years and older) and able to speak English.
Exclusion criteria
Not applicable as our focus on quitline clients and representatives (adults) of the quitline community or the healthcare sector.
Participants will receive the LCS educational materials, decision coaching call for the SDM visit, and navigation for LCS.
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0
Contact information is provided by the study sponsor or research team.
M.D. Anderson Cancer Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07630168
Bronchial Neoplasms, Carcinoma
Chapel Hill, North Carolina, United States
View Trial DetailsNCT07625644
Bronchial Neoplasms, Carcinoma
View Trial DetailsNCT07700823
Lung Cancer, Lung Diseases
View Trial DetailsNCT07676383
Breast Cancer, Breast Diseases
View Trial Details